Fullerton Fund Management’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Fullerton Fund Management’s Portfolio XPH Stock Details XPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-16,731	Closed	-$703K	–	79
2022 Q2	$703K	Sell	16,731 -31,896	-66%	-$1.34M	0.05%	50
2022 Q1	$2.2M	Buy	+48,627	New	+$2.14M	0.12%	45

Other funds holding XPH

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

CX Institutional Auburn, Indiana $3.46B AUM 21.89% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

Fullerton Fund Management's XPH Position: Q3 2022 in Review

Fullerton Fund Management sold out of State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q3 2022, closing a stake of 16,731 shares — an estimated $703K sold.

Fullerton Fund Management first reported a position in XPH in Q1 2022 and held it in 2 quarters. The position peaked at $2.2M in Q1 2022. 66 funds tracked by Wall St. Rank hold XPH as of Q3 2022.

Fullerton Fund Management reported no remaining State Street SPDR S&P Pharmaceuticals ETF position as of Q3 2022 after selling out during the quarter.
Fullerton Fund Management sold 16,731 State Street SPDR S&P Pharmaceuticals ETF shares in Q3 2022, an estimated $703K.
Fullerton Fund Management first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q1 2022 and held it in 2 quarters.
Fullerton Fund Management's State Street SPDR S&P Pharmaceuticals ETF position peaked at $2.2M in Q1 2022.
66 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q3 2022.

Based on Fullerton Fund Management's 13F filing for Q3 2022, filed 14 Nov 2022.